GTC
RCKT icon

Ghost Tree Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Ghost Tree Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-295,000
Closed -$6.04M – 65
2023
Q3 		$6.04M Buy
+295,000
New +$5.36M 1.99% 17
2017
Q1 		– Sell
-75,000
Closed -$1.83M – 79
2016
Q4 		$1.83M Buy
75,000
+69,825
+1,349% +$1.99M 0.44% 56
2016
Q3 		$196K Buy
+5,175
New +$163K 0.03% 88

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ghost Tree Capital's RCKT Position: Q3 2023 in Review

Ghost Tree Capital sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 75,000 shares — an estimated $1.36M sold.

Ghost Tree Capital first reported a position in RCKT in Q3 2016 and held it in 20 quarters. The position peaked at $27.4M in Q4 2020. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

  • Ghost Tree Capital reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 75,000 Rocket Pharmaceuticals shares in Q3 2023, an estimated $1.36M.
  • Ghost Tree Capital first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 20 quarters.
  • Ghost Tree Capital's Rocket Pharmaceuticals position peaked at $27.4M in Q4 2020.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.